This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Boston Scientific Feels Guidant's Pain

Boston Scientific (BSX - Get Report) is recalling a group of pacemakers and defibrillators, all of which were made by the business that used to be the stand-alone company Guidant, because the devices could fail.

The recall covers the Insignia and Nexus pacemakers, Contak Renewal TR/TR2 cardiac resynchronization pacemakers and Ventak Prizm 2, Vitality and Vitality 2 implantable cardioverter defibrillators. The products are made by Boston Scientific's cardiac rhythm management group that was formerly part of Guidant.

Boston Scientific, based in Natick, Mass., said it had recently identified a low-voltage capacitor in the devices that isn't performing properly. A capacitor is an electrical-charge storage component.

Some capacitors, if not working properly, could lead to a malfunction. To date, five defects have been confirmed, but no deaths have been reported. Roughly 27,200 of the devices have been implanted.

Product recalls are nothing new to Guidant. Boston Scientific acquired the company on April 21 after prevailing in a bidding war with Johnson & Johnson (JNJ - Get Report). J&J had originally planned to buy Guidant, but balked last year after the company recalled thousands of heart devices over several months.

Ultimately, J&J said it would still finish the deal, but at a lower price. However, Boston Scientific emerged with a higher bid, and after a series of amended proposals ended up with Guidant.

Shares of Boston Scientific were trading at a 52-week low, dropping $1.33, or 7.3%, to $16.93. The stock's lowest close in the past year is $18.06, and its high is $29.35. Volume was more than twice as heavy as normal.

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
BSX $17.11 1.40%
JNJ $102.18 0.21%
AAPL $95.99 1.10%
FB $102.07 2.50%
GOOG $698.66 3.00%


Chart of I:DJI
DOW 16,133.20 +118.82 0.74%
S&P 500 1,870.00 +17.79 0.96%
NASDAQ 4,340.1090 +71.3460 1.67%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs